Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AnaptysBio, Inc. before investing.

In this article, we go over a few key elements for understanding AnaptysBio, Inc.’s stock price such as:

• AnaptysBio, Inc.’s current stock price and volume
• Why AnaptysBio, Inc.’s stock price changed recently
• Upgrades and downgrades for ANAB from analysts
• ANAB’s stock price momentum as measured by its relative strength

About AnaptysBio, Inc. (ANAB)

Before we jump into AnaptysBio, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Want to learn more about AnaptysBio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AnaptysBio, Inc..

AnaptysBio, Inc.’s Stock Price as of Market Close

As of December 09, 2025, 4:00 PM, CST, AnaptysBio, Inc.’s stock price was $43.800.

AnaptysBio, Inc. is down 1.6% from its previous closing price of $44.510.

During the last market session, AnaptysBio, Inc.’s stock traded between $42.800 and $45.280. Currently, there are approximately 27.83 million shares outstanding for AnaptysBio, Inc..

AnaptysBio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

AnaptysBio, Inc. Stock Price History

AnaptysBio, Inc.’s (ANAB) price is currently up 5.16% so far this month.

During the month of December, AnaptysBio, Inc.’s stock price has reached a high of $46.560 and a low of $40.010.

Over the last year, AnaptysBio, Inc. has hit prices as high as $46.560 and as low as $12.210. Year to date, AnaptysBio, Inc.’s stock is up 230.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AnaptysBio, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 08, 2025, there were 0 analysts who downgraded AnaptysBio, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate AnaptysBio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AnaptysBio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AnaptysBio, Inc. (ANAB) by visiting AAII Stock Evaluator.

Relative Price Strength of AnaptysBio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 08, 2025, AnaptysBio, Inc. has a weighted four-quarter relative price strength of 33.52%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how AnaptysBio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AnaptysBio, Inc. Stock Price: Bottom Line

As of December 9, 2025, AnaptysBio, Inc.’s stock price is $43.800, which is down 1.6% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AnaptysBio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.